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1. Introduction 
Cardiovascular diseases are the main cause of death in many developed and developing 
countries around the world. Cardiovascular end points (myocardial infarction, stroke or 
sudden death) are strictly connected with prevalence of classic cardiovascular risk factors, 
such as smoking, sedimentary lifestyle, obesity, atherosclerotic lipid pattern and arterial 
hypertension. Also, many ‘new’ factors have been identified, e.g. hyperhomocysteinemia, 
increased fraction of small, dense LDL or lipoprotein (a), increased C-reactive protein, 
increased apo-B/apo-A ratio or some enzymes’ increased activities (Skoczynska, 2006). 
However, traditional risk factors alone (nonmodifiable and modifiable alike) do not fully 
explain high incidence and mortality from these diseases. The effectiveness of different 
strategies concentrating on reducing known risk factors does not translate to a satisfactory 
reduction of incidence and mortality from myocardial infarction or stroke. It is essential to 
introduce strategies concerning ‘new’ risk-factors, as well as to identify those that remain 
unknown. 
Heavy metals, such as lead, cadmium and mercury, are the most abundant xenobiotics in 
human environment. These metals are present in the air, house dust, soil, water, consumer 
products and some herbal remedies. Main toxicological problems result from these metals’ 
accumulation in soil, water, plants and animals, which is responsible for human exposure to 
toxic metals many years after the cessation of the emission. The intrauterine exposure, 
which is  especially dangerous, as metals pass the placental barrier (Bellinger et al., 1987), as 
well as lead exposure in early childhood (Roy et al., 2009), affects strongly immature tissues, 
mainly the central nervous system. Lead exposure during pregnancy has a clear impact on 
mental and behavioral development (Hu et al., 2006; Nie et al., 2011). It has been 
documented that there is no safe lead blood level and that its toxic action is present at levels 
much lower than previously suspected. Another problem is the existence of combined 
exposure to heavy metals, toxic and essential alike, in human natural environment. The 
disturbance in the homeostasis of trace metals (zinc, copper, calcium, iron, selenium) affects 
lead toxicity in the cardiovascular system (Faure et al., 1991; Kuliczkowski et al., 2004; 
Skoczynska et al., 1994). 
Although the knowledge on low lead exposure effects on the heart and blood vessels is 
incomplete, it seems justified to put forward a thesis that environmental exposure to lead is a 
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risk factor for developing a cardiovascular event. In case of this thesis’ positive verification, 
conducted studies, aside from contributing new facts to the knowledge on lead toxicity, may 
become a set-point for solving practical issues, i.e. means for identification and reduction of 
lead exposure sources, diagnosis and monitoring of lead toxicity, prophylaxis and treatment of 
individuals with an increased body lead burden. This would allow to achieve long-term social 
benefits, such as a decrease in incidence and mortality from cardiovascular diseases. 
2. The global decrease in exposure to lead 
Together with industrialization and motorization, the world lead production had been 
rising till 1980s, when it reached over 3.8 million tons per year (Kelly & Matos, 2005). 
However, since the 1990s, in general, the exposure to lead around the world has declined. It 
has been caused by the elimination of leaded petrol, the decrease in sales of lead containing 
water pipes and canned foods, and the recall from production of lead containing paints. 
In 1991, US Centers for Disease Control and Prevention (CDC) adopted the blood lead level 
of 10 µg/dL as a threshold for lead toxicity. In 1995, the same value was assumed by the 
World Health Organization. The United States National Health and Nutrition Examination 
Surveys (NHANES) have documented a dramatic decline in blood lead concentrations in US 
adults and children (Muntner et al., 2005). A  decline in blood lead level has been found also 
in Australia (Rossi, 2008). 
Despite legislative changes, in some developing countries the exposure to lead persists on 
an unchanged level. Only in 2000, in about 100 countries there was an exposure to leaded 
petrol. Lead is also used in the production of paints that are employed in maritime industry 
or to paint external building parts (Tong et al., 2000). In industrialized Asian, South and 
Latin American regions, also lead mining, smelting, battery factories, cottage industries, 
crystal glass foundries and glazed ceramics manufacturing are important antropogenic lead 
sources. In the nineties, in some industrial areas of China, the proportion of children with 
blood lead level exceeding 10 µg/dL reached 99% but in non-industrial regions was about 
50% (Shen et al. 1996). Among children older than 18 months, living in the area of Mexico 
City, 44% had blood lead level higher than 10 µg/dL (Romieu et al., 1995). Similarly, in 
populations of children living in industrial regions of India, these proportions were 
disturbingly high and ranged from 40% to 62% (Conference on Lead Poisoning, Bangalore, 
1999). 
Still, the worst situation concerns Africa and is caused by lack of legislative regulations, low 
number of epidemiologic studies and little toxicological information  (Mathee et al., 2006). 
In many developed European countries, i.e. Belgium, Germany, Sweden and the United 
Kingdom, there was a decline in blood lead level between 1978 and 1988 (Tong et al., 2000). 
The research project entitled Public Health Impact of long-term, low-level Mixed Element 
exposure (PHIME) in a susceptible population revealed that the European population has 
been subjected to a dramatically lower exposure to lead since the abolition of lead from 
petrol. In spite of this fact, at PHIME Seminar ‘Effects of exposure to metals; no margin of 
safety in Europe’ at the European Environment Agency on 10th of February 2011, it was 
emphasized that ‘lead pollution sources must continually be hunted down and stopped’. 
This recommendation is based on the observation that the level of exposure to lead 
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associated with a reduced IQ in children seems to be much lower than previously known 
(Report of PHIME, 2011). 
The exposure to lead in populations of Central-Eastern European countries is still 
dangerously high (Bogunia et al., 2007; Pawlas et al., 2008; Trzcinka-Ochocka et al., 2005). It 
is a consequence of political and economical neglect in the last decades. One of the main 
problems is lack of information on the factual level of environmental lead exposure. 
3. The dependence of circulatory system changes on body lead burden 
Lead does not fulfill any physiological function in the body and can be toxic even at a small 
blood concentration. At present, it is well documented that some neurological and 
cardiovascular effects of lead emerge at a blood lead level lower than adopted as a 
threshold, i.e. below 10 µg/dL. It has been estimated that blood lead level in a natural, non-
contaminated environment amounts to 0.016 µg/dL, i.e. about 600 times lower than the 
standard adopted for children by the CDC (Flegal & Smith, 1992). In the 1980s-90s, it was 
shown that lead-induced hypertension develops as a result of the environmental exposure 
associated with the blood lead concentration of 10-40 µg/dL (Cheng et al., 2001; Harlan et 
al., 1985; Pirkle et al., 1985). Simultaneously, lead-induced changes in blood pressure were 
not large. Results of 31 meta-analyses showed only a slight increase in blood pressure at a 
doubled blood lead level; on average 1 mmHg for systolic and 0.6 mmHg for diastolic 
pressure (Nawrot & Staessen, 2002). 
Also other studies performed in the 1980s-90s showed a toxic action of lead at a relatively 
low exposure, i.e. corresponding to the blood lead concentration of less than 25 µg/dL 
(Tong et al., 1998). In 2006, in Circulation, Menke et al. published data from NHANES 
analysis showing the association between blood lead level and mortality from both 
myocardial infarction and stroke. This association was significant at the lead level lower 
than 10 µg/dL (Menke et al., 2006). 
The dependence of changes in the circulatory system on blood lead level is not clear. On the 
basis of literature, it seems likely that there is an inverse relationship, i.e. a lower exposure is 
associated with greater cardiovascular changes, similarly to the case of neurotoxic effects of 
lead in children (Lanphear et al., 2005). 
In population studies of people exposed to lead, lead is determined in blood, urine and 
bone. The most frequently measured indicator of exposure is the blood concentration. Due 
to a relatively short half-life of lead in the blood (approximately 30 days), this biomarker 
does not reflect the body lead burden but rather a recent exposure to external or intrinsic 
sources (e.g. lead released into the blood from storage sites, in conditions such as acidosis, 
fever or infection). Therefore, a more reliable indicator of quantities of lead accumulated in 
the body is the bone concentration. Lead is measured in the skeletal system (in the tibia or in 
the patella) using the method of K-shell x-ray fluorescence (KXRF) (Arora et al., 2009). 
The positive correlation between blood lead level and arterial pressure has been well 
documented. However, lead concentration in the patella better correlates with the 
occurrence of coronary heart disease than arterial hypertension. Also, it has been suggested 
that blood lead level is a better predictor of cardiovascular diseases in young people, and 
lead concentration in the skeleton in elderly (Weisskopf et al., 2009). 
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4. The lead effect on the cardiovascular system 
4.1 Lead and arterial blood pressure 
On the basis of numerous population studies in different settings, including prospective 
studies, it has been well documented that lead induces arterial hypertension. The majority 
of cross-sectional and prospective studies showed a significant association between blood 
lead level and systolic or diastolic blood pressure (Apostoli et al., 1992; Ding et al., 1998; 
Hu et al., 1996; Malvezzi et al., 2001; Micciolo et al., 1994; Schwartz, 1991; Takebayashi et 
al., 2011; Tsao et al., 2000; Weiss et al., 1988). These associations have been found in 
populations with different geographic, ethnic, and socioeconomic backgrounds (Martin et 
al., 2006). A positive correlation was also established between umbilical blood lead level 
and the occurence of arterial hypertension in pregnancy (Rabinowitz et al., 1987). The 
development of hypertension in workers chronically exposed to high lead levels has been 
interpreted as a consequence of lead-induced nephropathy (Agency for Toxic Substances 
and Disease Registry, 1999; U.S. Environmental Protection Agency, 2006). However, in 
workers occupationally exposed to lower than nephrotoxic lead levels, low blood lead 
concentration was found as a predictor of an increased systolic blood pressure (Sirivarasai 
et al., 2004; Telisman et al., 2001). Similarly, prospective studies showed a correlation 
between lead bone concentration and systolic blood pressure (Cheng et al. 2001; Glenn et 
al., 2003). 
The impact of confounding factors on the relationship between body lead burden and 
arterial blood pressure can be reduced in experimental studies. Results of many studies 
performed on numerous experimental models, on various experimental animals (rats, 
rabbits, calf), have confirmed the hypertensive effect of small doses of lead and explained 
various mechanisms of this action. These mechanisms result from lead action on the central 
and peripheral nervous system (Hoffer et al., 1987; Nehru & Sidhu 2001; Silbergeld 1992; 
Reckziegel et al., 2011), the vessel wall (Ding et al., 1998; Dursun et al., 2005), the renin-
angiotensin system (Rodriguez-Iturbe et al., 2005; Sharifi et al., 2004), the kallikrein system 
(Carmignani et al., 1999), metabolic processes (Skoczynska et al., 1993; Skoczynska et al., 
2004), the generation of free radicals (Stohs & Bagchi 1995; Vaziri et al. 2001; Vaziri & Sica 
2004), and intracellular signalling pathways (Carmignani et al., 2000), leading to an increase 
in the vascular tone, and the peripheral vascular resistance (Fig. 1). 
It has been concluded that the evidence is sufficient to infer a causal relationship between 
lead exposure and arterial hypertension (Brown et al., 2011; Navas-Acien et al., 2007; 
Weisskopf et al., 2009). However, the most important mechanisms explaining the 
hypertensive effect of chronic low exposure to environmental lead still need an explanation. 
Hypertension induced by high doses of lead can be partially explained by the nephrotoxic 
action of this metal (Batuman, 1993; Navas-Acien et al., 2009). It is possible that also in low-
lead exposed individuals an impaired renal function is responsible for a persistent increase 
in blood pressure, as an inverse association between the glomerular filtration rate and blood 
lead has been observed in people with blood lead levels as low as 10 μg/dL (Fadrowski et 
al., 2010), or even 5 μg/dL (Ekong et al., 2006). One of the problems to examine in the future 
is the exploration of dose – response relationship and the determination of the latency 
period for lead – induced hypertension. 
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Fig. 1. Cardiovascular mechanisms of the hypertensive effect of low doses of lead 
(Skoczynska, 2006) 
4.2 Lead and atherosclerosis 
Aside from arterial hypertension, small amounts of lead cause also metabolic, functional 
and structural changes in the vessel wall. Some of these changes can accelerate the process 
of atherosclerosis. In the 1980s, in animal models, low-lead doses induced atherosclerosis 
was obtained (Revis et al., 1980,1981). Long-term lead exposure, measured by body lead 
store, was identified as a potential risk of intracranial carotid atherosclerosis in human (Lee 
et al., 2009). Some of the documented pro-atherosclerotic changes include: changes in lipid 
metabolism (Gatagonova, 1994; Kasperczyk et al., 2005a), endothelial dysfunctions (Ding et 
al., 1998; Vaziri et al., 2001), disturbances in essential metals’ homeostasis (De Castro et al., 
2010; Othman and Missiry, 1998; Wang et al., 2011), as well as an increase in free radicals’ 
generation (Stohs and Bagchi 1995; Vaziri et al. 2001), a procoagulant state (Fujiwara et al., 
2000; Kaji et al., 1991) and an inflammatory response (Heo et al., 1998) (Fig. 2). 
In our previous studies performed on experimental animals exposed to small doses of lead, 
we have shown that an increased vessel wall reactivity to the catecholamines 
vasoconstricting action (Skoczynska et al., 1986; Skoczynska et al., 1987; Skoczynska et al., 
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2001), an impaired vasodilatatory effect of acetylcholine (Skoczynska et al., 2005) and 
changes in vasoactive mediators blood levels (Skoczynska et al., 2003) are preceded by 
atherogenic dyslipidemia (Skoczynska et al., 1993), an increased lipid peroxidation, 
especially in the brain (Skoczynska et al.,1994), changes in the renin-angiotensin system 
(Wrobel & Skoczynska, 2002), and copper and zinc homeostasis (Skoczynska et al., 1994). In 
copper foundry workers exposed to lead, we have observed changes in vasoactive 
mediators blood levels (Skoczynska et al., 2002), hypertriglyceridemia (Skoczynska et al., 
2007), an increased serum lipid peroxidation (Turczyn et al., 2010) and changes in copper 
and zinc homeostasis (Skoczynska et al., 2001). 
 
Fig. 2. Possible mechanisms of the pro-atherosclerotic action of lead (Skoczynska, 2006) 
4.3 Lead and intermediate or immediate cardiovascular end points 
Lead-induced changes in the circulatory system affect the occurrence of cardiovascular end 
points in lead exposed populations. Intermediate indicators of these events are functional and 
structural changes in the heart, such as changes in the left ventricular mass, heart rate, heart 
rate variability or electrocardiographic abnormalities. The 24-hour electrocardiographic 
evaluation performed in our centre in groups of men occupationally exposed to lead (copper 
foundry workers) showed that various heart rhythm disorders were more frequent as 
compared to the controls. A more frequent incidence of tachycardia (Gajek et al., 2004; Poręba 
et al., 2010a), a decreased heart rate variability (Poręba et al., 2011), and abnormal parameters 
of heart rate turbulence (Poręba et al., 2010a) were observed. In another group of men with 
arterial hypertension, occupationally exposed to lead, the study has demonstrated a 
significantly more frequent manifestation of left ventricular diastolic dysfunction and an 
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increase in local arterial stiffness (Poręba et al., 2010b). However, lead exposed workers 
without hypertension also had an impaired diastolic function, compared with nonexposed 
controls (Beck & Steinmetz-Beck, 2005). In our earlier study, it was estimated that a ten-year 
risk of fatal cardiovascular disease (SCORE) in crystal glassworks’ employees exposed to lead 
was higher in comparison to other workers (Doroszko et al., 2008). Also lipid disturbances 
were associated with the occupational exposure to lead (Skoczynska et al., 2007). All these 
changes were related to a relatively high blood lead level (above 40 µg/dL). Our newest 
experimental studies, using nuclear magnetic resonance, seem to confirm an increased 
incidence of left ventricular diastolic dysfunction in rats poisoned with small doses of lead 
(data in press). 
In other studies, steel workers (Kasperczyk et al.,2005b) or battery workers (Tepper et al., 
2001) exposed to lead displayed a higher left ventricular mass and/or a lower ejection 
fraction, compared to administrative workers from the same factories. On the other hand, in 
other studies, the interventricular septum and the left ventricular wall thickness determined 
in refinery workers with high blood lead level were similar to those determined in workers 
with lower blood lead concentration. Simultaneously, the decrease of diastolic cardiac 
function was more significant in the lead poisoned group (Zou et al., 1995). It may be 
concluded that results of studies performed on populations occupationally exposed to lead 
are inconsistent and the data on how lead affects the heart is insufficient. It remains 
unknown, for example, if lead, regardless of its hypertensive effect, leads to left ventricular 
diastolic dysfunction or changes heart rate variability. 
There is no conclusion regarding the exact nature of lead influence on ECG. Since the 1970s, 
it has been known that lead increases heart sensitivity to noradrenaline arrhythmogenic 
action and causes bradycardia. Lead negative chronotropic action was associated with the 
blocking of heart beta adrenoreceptors activity (Bertel et al., 1978; Tsao et al. 2000). In 
various electrocardiographic studies, a significantly higher prevalence of heart ventricles 
repolarization disorders and heart rhythm disturbances was observed in groups of workers  
exposed to lead, in comparison to controls (Gatagonova 1995; Sroczynski et al., 1990). 
Among 775 men who participated in the Normative Aging Study, bone lead levels were 
found to be positively associated with heart rate, corrected QT and QRS intervals, especially 
in younger men. Additionally, a risk of intraventricular or atrioventricular block increased 
in men with elevated bone lead levels, whereas blood lead level was not associated with any 
of the electrocardiographic disturbances (Cheng et al., 1998; Eum et al., 2011). Authors of 
these studies suggest that the cumulative exposure to low lead levels causes 
electrocardiographic conduction disturbances. These disorders may be associated with the 
occurrence of different variants of genes involved in iron metabolism, such as 
hemochromatosis or heme oxygenase-1 genes. Park et al. found evidence that these genes’ 
variants increase the impact of low-level lead exposure on the prolonged QT interval (Park 
et al., 2009). However, intermediate cardiovascular outcome varied across studies, and 
findings were incoherent. 
Similarly, results of epidemiologic studies on the association between environmental low-
lead exposure and immediate cardiovascular disease end points (coronary heart disease, 
stroke and cardiovascular disease other than arterial hypertension) are inconsistent. One of 
the first studies that analyzed a correlation between blood lead level and the incidence of 
coronary heart disease or stroke was The British Regional Heart Study. In this study, 7371 
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men aged 40 to 59 from 24 British towns were followed-up for 6 years. After allowing 
confounding effects of cigarette smoking and a town of residence, there was no evidence 
that blood lead level is a risk factor for major ischemic heart disease or stroke (Pocock et al., 
1988). Also the study performed among 1052 inhabitants of Copenhagen County, who had 
the mean blood lead concentration of about 7 μg/dL in women and 18 μg/dL in men, and 
were observed for over 14 years, demonstrated a significant (p<0.03) risk for total mortality 
associated with blood lead but the risk for fatal and nonfatal cardiovascular disease or 
coronary complications was not significant (Møller & Kristensen, 1992). 
On the contrary, studies published during 2002-2006 showed an increased cardiovascular 
mortality in the general population environmentally exposed to lead among individuals 
with blood lead levels from 20 µg/dL to 5 µg/dL. 
The Second National Health and Nutrition Examination Survey (NHANES II), a national 
cross-sectional survey of the general US population conducted from 1976 to 1980, showed 
that individuals with blood lead levels of 20 to 29 µg/dL between 1976 and 1980 (15% of the 
US population at the time) experienced significantly increased all-cause, circulatory, and 
cardiovascular mortality from 1976 through 1992. After including the role of potential 
confounders, individuals with baseline blood lead levels of 20 to 29 µg/dL had a 46% 
increase in all-cause mortality (rate ratio (RR), 1.46; 95% confidence interval (CI), 1.14-1.86) 
and a 39% increase in circulatory mortality (RR, 1.39; 95% CI, 1.01-1.91), when compared to 
those with blood lead levels of less than 10 µg/dL (<0.5 µmol/L). All-cause mortality for 
those with blood lead levels of 10 to 19 µg/dL (0.5-0.9 µmol/L) was intermediately increased 
and statistically insignificant (Lustberg & Silbergeld, 2002). 
The association between blood lead levels and increased all-cause and cardiovascular 
mortality was observed also at blood lead levels substantially lower than 20 µg/dL. In the 
Third National Health and Nutrition Examination Survey, which from 1988 to 1994 
recruited 13,946 adult participants who were followed-up for up to 12 years for all-cause 
and cause-specific mortality, the geometric mean blood lead level in study participants was 
2.58 µg/dL. After the multivariate adjustment, hazard ratios (95% CI) of participants in the 
highest tertile of blood lead (≥ 3.62 µg/dL) and those in the lowest tertile (< 1.94 µg/dL) 
were 1.25 (1.04 to 1.51; P(trend) across tertiles = 0.002) for all-cause mortality and 1.55 (1.08 
to 2.24; P(trend) across tertiles = 0.003) for cardiovascular mortality. Blood lead level was 
significantly related to both myocardial infarction and stroke mortality, and the association 
was evident at levels ≥ 2 µg/dL) (Menke et al., 2006). 
The second study based on the Third NHANES US community concerned 9,757 participants 
≥ 40 years old put in three categories, depending on blood lead level: <5 µg/dL (the 
reference category), 5 to <10 and ≥10 µg/dL. The relative risk of mortality from all causes 
was 1.24 (95% confidence interval (CI), 1.05-1.48) for those with blood levels of 5 to <10 
µg/dL and 1.59 (95% CI, 1.28-1.98) for those with blood levels ≥ 10 µg/dL (p for trend < 
0.001) (Schober et al., 2006). To conclude, both studies based on the Third NHANES have 
documented an association between blood lead below 10 µg/dL and mortality among U.S. 
adults. 
Also occupational exposure seems to be associated with an increased risk of cardiovascular 
diseases. In 1963, Dingwall-Fordyce and Lane published results of an analysis of the causes 
of death among workers who had been exposed to lead. There were 425 pensioners, 184 of 
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whom had died; additionally, 153 deaths occurred among an unknown number of 
employees who had not yet reached the retirement age. This analysis provided evidence 
that heavy exposure to lead was associated with an increased incidence of deaths from 
cerebrovascular catastrophes (Dingwall-Fordyce & Lane, 1963). The study of 1261 
typesetters exposed to low lead doses, started in 1961 and followed until the end of 1984, 
confirmed the increased cerebral mortality in workers subjected to prolonged exposure. The 
all-cause standardized mortality ratio was 0.74, the cardiac mortality ratio was 0.63, whereas 
the ratio for cerebrovascular disease was 1.35 (at the edge of statistical significance). For 
printers employed for 30 years or more, the cardiovascular mortality ratio was 1.68 (95% CI: 
1.18-2.31; p = 0.002) (Michaels et al., 1991). In turn, in the prospective study described by 
Robinson in 1974, over 20 years (1947-67) the risk of mortality in a group of 592 tetraethyl 
lead workers and in a group of 660 non-exposed workers was similar. No difference 
between the two groups in either total mortality or mortality from specific diseases was 
found (Robinson, 1974). Other retrospective observation which covered 4.556 workers 
occupationally exposed to lead, diagnosed during 1970-1992, revealed increased total 
mortality (670 deaths; SMR = 108; 95% CI: 100-116) in comparison to the general population. 
However, the risk of cardiovascular mortality was significantly increased only in the 
subcohort with high exposure (153 deaths; SMR = 129; 95% CI: 109-151) (Wilczynska et al., 
1998). 
In analyses of results obtained from 13,043 South Korean lead workers with mean geometrical 
blood lead level of 6.01 µg/dL, the impact fractions for cardiac disease among lead workers 
would be estimated as about 5-13 times higher than those of the general population. 
Manufacture of accumulators, manufacture of other electronic valves, tubes, and components, 
and manufacture of accessories for motor vehicles were identified as a relatively important 
industry. Other industrial processes of relative importance included battery assembly, acid 
treatment and other soldering (Kim et al., 2008). Also in population of 420 male bus drivers in 
Thailand, with blood lead level ranging from 2.5 to 16.2 µg/dL (the mean of 6.3 ± 2.2 µg/dL), 
using the second derivative finger photoplethysmogram (SDPTG) as a marker of the 
cardiovascular risk, and allowing age, body mass index and lifestyle factors, a significant 
correlation between blood lead and SDPTG-AI was found (Kaewboonchoo et al., 2010). 
4.4 Lead and peripheral artery disease 
There have been no prospective studies on the association of blood lead with peripheral 
arterial disease (PAD). However, the relative risk for PAD, comparing blood lead levels ≥ 
2.47 μg/dL versus < 1.03 μg/dL, in a cross-sectional analysis of NHANES 1999–2002, was 
1.92. Data was obtained from 1999 to 2000, from 2125 participants who were ≥ 40 years of 
age. Peripheral arterial disease was defined as a condition with an ankle brachial index 
lower than 0.9 in at least one leg (Muntner et al., 2005). After adjustment for demographic 
and cardiovascular risk factors, the odds ratios of peripheral arterial disease, comparing the 
second, third and fourth quartile of blood lead level with the lowest quartile, were 1.63, 1.92 
and 2.88, respectively. It was concluded that blood lead (as well as cadmium) is associated 
with an increased prevalence of peripheral arterial disease in the general U.S. population 
(Navas-Acien et al., 2004). Simultaneously, lead levels in urine (contrary to cadmium) were 
not associated with PAD at the levels found in this population (Navas-Acien et al., 2005). In 
turn, the observed association of homocysteine level and PAD can be completely explained 
by confounding due to smoking, increased blood lead and cadmium levels and impaired 
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renal function (Guallar et al., 2006). The disturbances in homocysteine metabolism (Poręba 
et al., 2005) and the negative linear correlation between blood lead levels and the ankle-
brachial index (Doroszko et al., 2008) were found also in workers occupationally exposed to 
lead; however, the latter relationship was discovered only in a subgroup of workers with a 
normal lipid pattern. Results obtained by Schafer et al. showed that hyperhomocysteinemia 
could be a mechanism that underlies lead effects on the cardiovascular and central nervous 
systems, possibly offering new targets for prevention of long-term consequences of lead 
exposure (Schafer et al., 2005). 
In 2009, Weisskopf  et al. published results of the analysis of all observational studies from 
database searches and citations regarding lead, intermediate and immediate cardiovascular 
end points. Studies in general populations have identified a positive association between 
lead exposure and coronary heart disease, cardiac mortality, cerebral mortality and 
peripheral arterial disease. Estimates of the relative risk of cardiovascular mortality in 
workers exposed to lead varied widely across occupational studies; with positive, inverse or 
null correlations. The positive association between lead levels and cardiovascular mortality 
occurred in workers with the heaviest exposure. Authors concluded that the evidence is 
suggestive but not sufficient to infer a causal relationship of lead exposure and clinical 
cardiovascular outcomes. There is also a suggestive but insufficient evidence to infer a 
causal relationship of lead exposure and heart rate variability (Weisskopf et al., 2009). 
5. Genetic polymorphisms and lead toxicity 
Human sensitivity to toxic effect of heavy metals differs depending on age, sex, general 
health status, quantitative and qualitative alimental deficiency, diet, smoking, lifestyle, place 
of inhabitancy and socioeconomical status, hygienic habituation, total occupational and 
environmental exposure to xenobiotics. Some of the critical effects of lead result from lead 
interference with enzymatic processes responsible for the synthesis of heme. These include 
the inhibition of delta-aminolevulinic acid dehydratase (ALAD), changes in the 
concentration of delta-aminolevulinic acid in urine (ALA-U), blood (ALA-B) or plasma 
(ALA-P), changes in the concentration of coproporhyrin in urine and zinc protoporphyrin 
(ZP) in blood. As a result of exposure to lead, there is a decrease in activity of blood 
pyrimidine nucleotidase (P5’N) and nicotinamide adenine dinucleotide synthetase (NADS), 
as well as changes in nucleotides’ blood content. All these effects have been used as 
biomarkers of lead toxicity (Skoczynska, 2006). Genetic polymorphisms that affect lead 
toxicokinetics and toxicodynamics may be important factors modifying the risk of harmful 
effects of lead in vulnerable populations. 
Differences in lead effect on the heme synthesis pathway, observed between different 
representatives of the same population exposed to lead, may be determined by different 
types of the ALAD gene. In turn, the differences between heme precursors levels in different 
ALAD genotypes can be related to a varied lead affinity to different ALAD isozymes. Thus, 
ALAD1 homozygotes (a genotype more frequent than ALAD 1-2) might be more susceptible 
to disturbances in heme metabolism caused by lead exposure than ALAD2 carriers (Sakai et 
al., 2000; Suzen et al., 2003). ALAD 1-1 subjects might be also more susceptible to the 
cytogenetic effect of lead than ALAD 1-2 subjects (Alexander et al., 1998; Dyudu & Suzen 
2003). ALAD polymorphisms may be also involved in the emergence of lead-induced 
arterial hypertension. In terms of exposure to large doses of lead, ALAD polymorphisms are 
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associated with lead-induced renal hyperfiltration (Weaver et al., 2003). It has been shown, 
that ALAD 1-2 variants affect the presence of the association between renal function and 
bone (the tibia or the patella) lead level. Similarly, variant B of the vitamin D receptor gene 
modifies renal sufficency, although only in young population exposed to high doses of lead 
(Weaver et al., 2006). Also the impact of endothelial nitric oxide synthase (eNOS) gene 
polymorphisms on kidney function has been demonstrated in employees exposed 
chronically to lead: the presence of the Asp allele was associated with higher serum 
creatinine than the genotype Glu/Glu (Weaver et al., 2003). Lead and selected genes, i.e. 
vitamin D receptor (VDR) and ALAD genes, may influence blood pressure and risk of 
hypertension. In a group of workers, 798 exposed to lead and 135 non-exposed, VDR 
genotypes (BB and Bb vs. Bb), lead concentration in the blood and in the tibia, and the 
amount of lead bound by dimercapto-succinic acid were all positive predictors of systolic 
blood pressure. Lead exposed individuals with the VDR B allele, mainly heterozygotes, had 
systolic blood pressures that were 2.7-3.7 mm Hg higher than in workers with the bb 
genotype. VDR genotype was also associated with diastolic blood pressure; lead workers 
with the VDR B allele had diastolic blood pressures that were 1.9-2.5 mm Hg higher than in 
lead workers with the VDR bb genotype (p = 0.04). In addition, compared to lead workers 
with the VDR bb genotype, workers with the VDR B allele had a higher prevalence of 
hypertension (adjusted odds ratio (95% confidence interval) = 2.1 (1.0, 4.4), p = 0.05) and a 
larger increase in blood pressure with age (Lee et al., 2001). 
In the analysis described by Scinicariello et al., on the basis of data obtained from adults 
who participated in the Third NHANES, whose DNA was available (n=6,016), multivariable 
logistic and linear regressions stratified by race/ethnicity were used to examine whether 
blood pressure was associated with the ALAD gene and blood lead levels. Blood lead level 
was associated with systolic pressure in non-Hispanic whites and with hypertension, 
systolic and diastolic pressures in non-Hispanic blacks, but not in Mexican Americans. Non-
Hispanic white ALAD2 carriers of the highest blood lead level quartile had a significantly 
higher adjusted prevalence odds ratio for hypertension compared with ALAD1 
homozygous individuals. In addition, a significant interaction between lead concentration 
and the ALAD2 allele, in relation to systolic blood pressure, was shown in non-Hispanic 
whites and non-Hispanic blacks (Scinicariello et al., 2010). 
Also a mutation of the hemochromatosis gene (HFE H63D) has been associated with 
changes in blood pressure, examined as the pulse pressure (the difference between systolic 
and diastolic blood pressure) within the Normative Aging Study between 1991-2001. 
Baseline bone lead levels, markers of the cumulative lead exposure, are associated with 
steeper increases in pulse pressure in men with at least one H63D allele (p-interaction = 0.03 
for tibia and 0.02 for patella), compared with men with only wild types or C282Y variant 
(Zhang et al., 2010). HFE variants are associated also with increased blood lead levels in 
young children (Hopkins et al., 2008). 
Lead induces arterial hypertension in the consequence of low exposure, which may be not 
manifested by a toxic effect on the marrow, kidneys or other organs. The existence of lead 
hypertensive effect, in the range of blood concentration lower than 40 µg/dL, has been 
supported by numerous experimental and population studies. However, the presence of a 
significant correlation between blood lead level and systolic and/or diastolic blood pressure 
has not been confirmed by all of performed epidemiologic tests. These discrepancies can be 
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explained by the fact that lead-induced hypertension results rather from the past than from 
the current exposure, and hence arterial pressure values should be rather related to bone 
than to blood lead level. The occurrence of polymorphisms of genes involved in lead toxic 
effect may stand for another explanation. Interactions between lead toxicity and ALAD or 
HFE genes polymorphisms were observed in occupational and epidemiologic studies. These 
polymorphisms, occurring singularly or in an association with other polymorphisms (e.g. 
the vitamin D receptor gene), seem to be involved in lead-induced hypertension. Results of 
experimental studies indicate that the correlation between lead exposure, arterial blood 
pressure and the presence of polymorphisms of angiotensin converting enzyme and 
beta(2)adrenergic receptor genes should be analyzed in the general population. It is likely 
that studies of these polymorphisms, gene-to-gene interactions and interactions between 
genes and environmental factors may provide the identification of causes of so called 
spontaneous hypertension (Skoczynska, 2008). 
6. Problems related to lead toxicity 
It has been established that low level exposure to lead induces arterial hypertension. 
However, the data of many studies is suggestive but insufficient to infer that low level 
exposure to lead increases the occurrence of cardiovascular end points. The causal 
interference between lead exposure and immediate as well as some of intermediate end 
points needs a further explanation. The dose-effect relationship in the cardiovascular action 
of lead also remains unclear. It is possible that only low and recent exposure to lead is 
associated with arterial hypertension. Perhaps, there is an inverse relationship between 
blood lead levels and blood pressure values, similarly as in neurotoxic effects of lead in 
young organisms. It is also possible that cardiac end points are associated with long-term 
exposure to lead, which would be implied by the existent relationship between the patella 
lead and the occurrence of coronary heart disease. 
Subsequently, blood lead level, most often determined spectrophotometrically, is variable 
and depends not only on external but also internal exposure. Factors such as fever, alcohol 
and acidosis cause a mobilization of lead from organs and from the skeleton. A single 
measurement of blood lead should be therefore verified, which is frequently practiced in 
occupationally exposed but would be difficult to apply to the general population. In turn, 
bone (the tibia or the patella) lead concentration, an established marker of accumulated lead, 
is determined using the method of K-shell x-ray fluorescence. This marker is more stable in 
comparison to blood lead but more difficult and expensive to measure. 
In the population analysis of data on lead cardiovascular effects, it is indispensable to 
determine the role of confounding factors. The presence of a greater number of these factors 
cause incoherence in studies’ results. Factors such as race, education, income, urban versus 
rural location and socioeconomic status should be considered. There are especially great 
difficulties in establishing how hypertension impacts relations between low exposure to lead 
and other than hypertension lead effects. Hypertension may result from lead action or occur 
independently but in each case constitutes a factor that confounds relations between lead 
and e.g. coronary heart disease or stroke. Similarly, disturbances in lipid and homocysteine 
metabolism or trace metals homeostasis may be simultaneously confounding factors and 
results of lead action. 
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7. Chelation treatment for lead poisoning 
The chelation treatment has historically been used to reduce body lead burden in patients 
with severe symptoms of poisoning with lead. Chelating agents are organic compounds 
capable of linking together metal ions to form complex ring-like structures, which are 
subsequently excreted with urine. Effectiveness of chelation depends on whether the 
chelating agent is able to reach the intracellular site where the heavy metal is firmly bound. 
This intracellular availability is conditioned by many factors, e.g. ionic diameter, 
intra/extracellular compartmentalization and excretion pathway. Hydrophilic chelators are 
most effective in metals’ excretion with urine, but they weaken complex intracellular metal 
deposits, whereas lipophilic chelators can redistribute toxic metals to lipid-rich organs, e.g. 
the brain (Andersen & Aaseth, 2002). 
The chelation is usually performed using calcium disodium ethylenediamine tetra acetic 
acid (CaNa2EDTA) and a preceeded administration of calcium. A contraindication to 
chelation is hypocalcemia or renal insufficiency. Also D-penicillamine and British anti-
lewisite (BAL) have been used as antidotes for acute and chronic poisoning. 2, 3-
dimercaprol (BAL) has long been the mainstay of chelation therapy for lead or arsenic 
poisoning. A thiol chelating agent, meso-2,3,-dimercaptosuccinic acid (DMSA), an analogue 
of BAL, has been tried successfully in animals as well as in a few cases of human lead and 
arsenic intoxication. DMSA could be a safe and effective method of treatment, but one of the 
major disadvantages of chelation with DMSA is its inability to remove lead from the 
intracellular sites because of its lipophobic nature (Kalia & Flora, 2005). 
Even after many years of chelation, an effective treatment of patient poisoned with lead is 
difficult to obtain. New trends in chelation therapy including combined treatment are 
promising. This includes the use of structurally different chelators or a combination of an 
adjuvant and a chelator to provide better clinical and biochemical recovery, in addition to 
lead mobilization. Kalia et al. compared the therapeutic efficacy of captopril and DMSA, 
either individually, or in combination, against arsenite induced oxidative stress and metal 
mobilization in rats. Interestingly, combined administration of captopril and DMSA had a 
remarkable effect in depleting total arsenic concentration from blood and soft tissues. In 
addition, captopril administration during chelation treatment had beneficial effects 
particularly on the protection of inhibited blood ALAD activity (Kalia et al., 2007). 
The therapeutic efficacy of melatonin or N-acetylcysteine (NAC) in reducing lead 
concentration in blood and other soft tissues was studied individually and in combination 
with DMSA. Administration of melatonin and NAC individually provided protection to the 
antioxidant defense, which disturbed by lead may significantly compromise a normal 
cellular function. Administration of melatonin and NAC (a thiol containing antioxidant) 
provided an increase in tiobarbituric acid levels, reduced glutathione and oxidized 
glutathione contents in tissues, which suggests these drugs’ ability to act as free radical 
scavengers and to protect cells against toxic insult. In turn, a combined treatment of DMSA 
and NAC provided more pronounced efficacy in restoring altered biochemical variables and 
in reducing body lead burden than monotherapy with DMSA. The results suggest the 
involvement of ROS in lead toxicity and a pronounced beneficial role of NAC in therapeutic 
implications of lead poisoning, when co-administered with a thiol chelator (DMSA). They 
also support the hypothesis that cellular redox status may be significantly reversed by 
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utilizing a thiol containing an antioxidant compound. Authors concluded that combined 
therapy with an antioxidant moiety and a thiol-chelating agent may be a better choice for 
treating plumbism (Flora et al., 2004a). 
It has been suggested that a concomitant administration of an antioxidant could play a 
significant and important role in abating a number of toxic effects of lead, when 
administered with thiol chelators. Flora et al. also investigated the effect of taurine, an 
amino acid and a known antioxidant, either alone or in combination with DMSA, in the 
treatment of subchronic lead intoxication in male rats. DMSA was able to increase the 
activity of ALAD, while both taurine and DMSA were able to significantly increase GSH 
level and bring them towards normal. In animals treated with taurine, there has been a 
reduction of changes of biochemical parameters indicative of oxidative stress, especially in 
the brain. The data also implied a promising role of taurine during chelation of lead, as a 
possible potentiator of the depletion of blood, liver and brain lead, compared to DMSA 
alone (Flora et al., 2004b). 
Chelation is a beneficial therapy in case of chronic intoxication with heavy metals. This 
therapy is of smaller significance in case of acute poisoning, which is a result of a complex 
clinical situation. Acute metal intoxication usually proceeds with multiorgan distress 
syndrome, determining contraindications to treatment with chelators. Symptoms of kidney 
or liver dysfunction limit credibility of indicators monitoring chelator’s effectiveness. As a 
rule, patients need the intensive care and symptomatic treatment. However, the moment 
chelators are allowed to include, the chelation therapy can determine the prognosis. In 
workers occupationally exposed to heavy metals, chelation can serve as a prognostic 
procedure, useful in occupational risk estimation. It also enables to undertake appropriate 
actions. Temporary or lasting discontinuation of work in exposition to lead, before clinical 
symptoms appear, results in a significant decrease in the occupational lead poisoning. 
However, due to metal accumulation in tissues, chelation is not a fully effective therapy and 
needs repeated doses of drugs, usually administered through the parenteral way. A 
combined therapy, an antioxidant plus chelator, does not seem to be the best choice for all of 
the patients poisoned with metals. This therapy can be beneficial only if an antioxidant is 
simultaneously a chelator, as it is in case of N-acetylcysteine. Then, the additive impact of 
both chelators is expected. The effectiveness of the therapy with an antioxidant is 
significantly dependent on patient’s oxidative status at the beginning of the treatment. This 
effect, due to the antioxidant potential, can be beneficial as well as aggravating. It concerns 
especially metals which do not undergo Fenton’s reaction: cadmium, lead, mercury. 
Additionally, the use of antioxidants without chelators, i.e. in the prevention of 
cardiovascular diseases, showed only equivocal benefits resulting from the antioxidant 
supplementation. Moreover, some of patients showed an increased number of 
cardiovascular end points and incidence of neoplasms. New long-term chelators, consisting 
of structurally different components (including N-acetylcysteine), are needed. 
To summarize, chelation is a common therapy in case of poisoning with toxic metals but it is 
only partially satisfactory because of metal accumulation in tissues. A combined therapy 
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In developed countries, workers occupationally exposed to lead at high concentrations (i.e. 
copper founders) are subjected to biological monitoring. Chelation, which is practised as a 
part of the monitoring, decreases body burden with toxic metals. In the nearest future, it is 
essential to began a study on the effect of chelation on arterial blood pressure and 
cardiovascular end points in workers exposed to lead.  
8. Plan for the future 
Current investigations, which will continue after previous clinical, epidemiologic and 
experimental studies, are to explain whether environmental exposure to lead is a risk factor 
for development of vascular changes in the heart, brain and legs. They are also designed to 
explain the role of homocysteine and lead-iron interactions in cardiac and vascular effects of 
lead. The final purpose of project is the assessment of environmental exposure to lead as a 
lowering average life expectation factor. 
Further cross-sectional and prospective studies, combined epidemiological and 
toxicological, on the presence of the relationship between blood lead concentrations and 
prevalence of coronary heart disease, stroke and peripheral artery disease are needed. 
Confounding factors’ (male sex, age over 65, smoking, hypertension, diabetes and abnormal 
lipid pattern) influence on studied relations should be considered. DNA isolation should be 
conducted in order to determine the frequency of genetic polymorphisms that may 
influence the presence of a relationship between blood lead levels and ischemic heart 
disease or stroke. It should also be researched whether polymorphisms of determined genes 
(e.g. beta receptor and vitamin D receptor genes, or PPAR alpha and lipoprotein lipase 
genes) affect lead-induced hypertension or lead-induced changes in the lipid pattern. 
Moreover, the determination of iron and homocysteine role in lead toxic effects is needed. 
Obtained results may confirm the thesis that environmental exposure to lead is a risk factor 
for developing a cardiovascular event. In case of a positive verification, conducted studies 
may become a set-point for solving practical issues, i.e. providing means of reducing sources 
of lead exposure and/or lead toxicity (chelators, antioxidants). Probably, current 
environmental safety standards for blood lead level ought to be lowered. A criterion for 
elevated lead exposure screening needs to be verified not only in children but also in adults. 
The risk assessment of lead exposure impact should include lead cardiovascular effects. The 
risk assessment of cardiovascular end points should include the information on lead 
exposure. 
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